Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EBITDA: 2018-2024

Historic EBITDA for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to -$2.6 million.

  • Eton Pharmaceuticals' EBITDA fell 367.78% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 48.67%. This contributed to the annual value of -$2.6 million for FY2024, which is 117.87% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported EBITDA of -$2.6 million as of FY2024, which was down 117.87% from -$1.2 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' EBITDA registered a high of -$1.2 million during FY2023, and its lowest value of -$27.1 million during FY2020.
  • For the 3-year period, Eton Pharmaceuticals' EBITDA averaged around -$4.0 million, with its median value being -$2.6 million (2024).
  • Per our database at Business Quant, Eton Pharmaceuticals' EBITDA skyrocketed by 94.49% in 2021 and then crashed by 452.51% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' EBITDA (Yearly) stood at -$27.1 million in 2020, then surged by 94.49% to -$1.5 million in 2021, then crashed by 452.51% to -$8.3 million in 2022, then soared by 85.57% to -$1.2 million in 2023, then tumbled by 117.87% to -$2.6 million in 2024.